The nation of Zimbabwe has declined a major American healthcare agreement valued at $367m (£272m) over five years over the United States' request for confidential data.
This rejection became public following a internal memorandum from December was leaked, revealing that President Emmerson Mnangagwa felt the arrangement was "skewed".
A government spokesperson later clarified that the US was requesting health data for research and profit but refused to guarantee the benefits from future medical innovations.
"We are forced to start the challenging and unfortunate task of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged further dialogue to reach a agreement suitable to all parties so the country's vital HIV programme can be sustained.
Wider Implications
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a high court suspended a similar deal with the US after legal challenges were filed about the security of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had overseen aid for the American government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral agreements to enhance transparency and responsibility.
Based on statements, Sixteen African countries have so far signed similar health pacts, representing more than $18.3bn in new funding.
Details of the Declined Deal
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, without any corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Effectively, our nation would supply the raw materials for medical research without any assurance that the resulting innovations would be accessible to our citizens if a future disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one deals were upending systems already established via the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing system created to manage potential pandemics.
"This mechanism is intended to ensure that when a nation contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome ongoing dialogue with our US partners on how subsequent co-operation could be structured in a manner that honours the independence and interests of both nations."
Health Experts Reaction
Medical experts expressed it recognised the government's concerns, but urged that negotiations need to persist considering much of the nation's Aids initiatives depended on external financing.
"If technical issues exist, such as those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," the group said.
This impasse underscores the ongoing debate between accepting much-needed foreign assistance and protecting a country's data in an increasingly interconnected world.